Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs

Simple item page
dc.contributor.advisorJackson, Graham E
dc.contributor.advisorBourne, Susan A
dc.contributor.authorVicatos, Giselle Marianthi
dc.date.accessioned2022-03-17T05:42:38Z
dc.date.available2022-03-17T05:42:38Z
dc.date.issued2021
dc.date.updated2022-03-17T05:42:15Z
dc.description.abstractRheumatoid arthritis (RA) is a debilitating disease affecting 5% of the world's population and there is no cure. Copper(II) complexes have been reported to have anti-inflammatory activity and alleviate the symptoms associated with the disease. The present study focuses on the design of new drugs that could be used to change the bioavailability of copper(II) and hence alleviate the inflammation. The tripeptides, glycyl-L-leucyl-L-histidine (GLH), sarcosyl-L-leucyl-Lhistidine (Sar-LH), glycyl-L-phenylalanyl-L-histidine (GFH) and sarcosyl-L-phenylalanyl-Lhistidine (Sar-FH) were designed to resemble the natural in vivo copper(II) transporter, human serum albumin, so that they could be selective for copper(II). The preferred route of administration is dermal absorption and so sarcosine was added to improve the lipophilicity of the drug. This administration method was chosen since it is both nonharmful and convenient for patients. The stability of the complexes was measured using glass electrode potentiometry and their solution structure studied using UV-Vis spectrophotometry, CW-EPR spectroscopy, 1H NMR, ESI-MS and molecular modelling calculations. The presence of sarcosine did not significantly affect the stability of the complexes. Several species were found to exist in solution depending on the pH, but at pH 7, the CuLH-2 species predominated for all four tripeptides. In this species, the ligand was found to coordinate to copper(II) via the terminal amine-N, the two amide-Ns and imidazole-N, in a square planar geometry. Using a computer model of blood plasma, all four ligands were found to mobilise copper(II), without disrupting the homeostasis of nickel(II), zinc(II) or calcium(II) in the order of GFH > Sar-FH > GLH > Sar-LH. GFH increased the low molecular mass copper(II) species by 40.7 times at 0.1 mM. The lipophilicity of the complexes was estimated by measuring their octanol/water partition coefficients. All the complexes were found to be hydrophilic with log Poct/aq ranging from -3 to -2. Dermal absorption was estimated using an artificial membrane and a Franz cell. Only a moderate increase in membrane permeability of copper(II) was found. The stability of the copper(II) complexes, their ability to mobilise copper(II) from endogenous sources and their improved dermal absorption, justifies further testing of this class of ligand as potential, dermally absorbable, anti-inflammatory drugs.
dc.identifier.apacitationVicatos, G. M. (2021). <i>Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs</i>. (). ,Faculty of Science ,Department of Chemistry. Retrieved from http://hdl.handle.net/11427/36156en_ZA
dc.identifier.chicagocitationVicatos, Giselle Marianthi. <i>"Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs."</i> ., ,Faculty of Science ,Department of Chemistry, 2021. http://hdl.handle.net/11427/36156en_ZA
dc.identifier.citationVicatos, G.M. 2021. Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs. . ,Faculty of Science ,Department of Chemistry. http://hdl.handle.net/11427/36156en_ZA
dc.identifier.ris TY - Doctoral Thesis AU - Vicatos, Giselle Marianthi AB - Rheumatoid arthritis (RA) is a debilitating disease affecting 5% of the world's population and there is no cure. Copper(II) complexes have been reported to have anti-inflammatory activity and alleviate the symptoms associated with the disease. The present study focuses on the design of new drugs that could be used to change the bioavailability of copper(II) and hence alleviate the inflammation. The tripeptides, glycyl-L-leucyl-L-histidine (GLH), sarcosyl-L-leucyl-Lhistidine (Sar-LH), glycyl-L-phenylalanyl-L-histidine (GFH) and sarcosyl-L-phenylalanyl-Lhistidine (Sar-FH) were designed to resemble the natural in vivo copper(II) transporter, human serum albumin, so that they could be selective for copper(II). The preferred route of administration is dermal absorption and so sarcosine was added to improve the lipophilicity of the drug. This administration method was chosen since it is both nonharmful and convenient for patients. The stability of the complexes was measured using glass electrode potentiometry and their solution structure studied using UV-Vis spectrophotometry, CW-EPR spectroscopy, 1H NMR, ESI-MS and molecular modelling calculations. The presence of sarcosine did not significantly affect the stability of the complexes. Several species were found to exist in solution depending on the pH, but at pH 7, the CuLH-2 species predominated for all four tripeptides. In this species, the ligand was found to coordinate to copper(II) via the terminal amine-N, the two amide-Ns and imidazole-N, in a square planar geometry. Using a computer model of blood plasma, all four ligands were found to mobilise copper(II), without disrupting the homeostasis of nickel(II), zinc(II) or calcium(II) in the order of GFH > Sar-FH > GLH > Sar-LH. GFH increased the low molecular mass copper(II) species by 40.7 times at 0.1 mM. The lipophilicity of the complexes was estimated by measuring their octanol/water partition coefficients. All the complexes were found to be hydrophilic with log Poct/aq ranging from -3 to -2. Dermal absorption was estimated using an artificial membrane and a Franz cell. Only a moderate increase in membrane permeability of copper(II) was found. The stability of the copper(II) complexes, their ability to mobilise copper(II) from endogenous sources and their improved dermal absorption, justifies further testing of this class of ligand as potential, dermally absorbable, anti-inflammatory drugs. DA - 2021 DB - OpenUCT DP - University of Cape Town KW - chemistry LK - https://open.uct.ac.za PY - 2021 T1 - Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs TI - Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs UR - http://hdl.handle.net/11427/36156 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/36156
dc.identifier.vancouvercitationVicatos GM. Development of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs. []. ,Faculty of Science ,Department of Chemistry, 2021 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/36156en_ZA
dc.language.rfc3066eng
dc.publisher.departmentDepartment of Chemistry
dc.publisher.facultyFaculty of Science
dc.subjectchemistry
dc.titleDevelopment of dermally absorbed copper(ii) complexes as potential anti-inflammatory drugs
dc.typeDoctoral Thesis
dc.type.qualificationlevelDoctoral
dc.type.qualificationlevelPhD
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_sci_2021_vicatos giselle marianthi.pdf
Size:
7.08 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
PhD / Doctoral